• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC - GALWAY PROMUS ELEMENT¿ PLUS; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC - GALWAY PROMUS ELEMENT¿ PLUS; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Model Number H7493911432220
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Cardiomyopathy (1764); Occlusion (1984)
Event Date 09/14/2017
Event Type  Injury  
Manufacturer Narrative
Device is a combination product.The device was not returned for analysis.A review of the manufacturing documentation found that all devices shipped from the batch conformed to the preventive measures / current controls as per product specification.The root cause is anticipated procedural complications as this event is a known physiological effect of the procedure and is noted within the dfu.(b)(4).
 
Event Description
Same case as mdr id#: 2134265-2017-10003 and 2134265-2017-10005.(b)(4) clinical study.It was reported that restenosis occurred.In (b)(6) 2013, index procedure was performed.Target lesion #1 was a de novo lesion located in the distal left circumflex artery with 95% stenosis and was 20 mm long with a reference vessel diameter of 2.60 mm.The lesion was treated with pre-dilatation and placement of a 2.50 x 24 mm promus element plus stent.Following post dilatation, residual stenosis was 0%.Target lesion #2 was a de novo and ostial lesion located in the proximal left anterior descending artery (lad) with 50% stenosis and was 30 mm long with a reference vessel diameter of 2.60 mm.The lesion was treated with direct placement of a 2.50 x 32 mm promus element plus stent.Following post dilatation, residual stenosis was 0%.Target lesion #3 was a de novo lesion located in the mid lad with 95% stenosis and was 28 mm long with a reference vessel diameter of 2.50 mm.The lesion was treated with pre-dilatation and placement of a 2.25 x 32 mm and 2.50 x 38 mm promus element plus stents in an overlapping manner.Following post dilatation, residual stenosis was 0%.On the following day, the patient was discharged on aspirin and clopidogrel.In (b)(6) 2017, the patient was hospitalized.Upon admission in emergency room, echo revealed newly decreased ejection fraction (ef) of 15-20%.The patient was diagnosed with ischemic cardiomyopathy.Due to the decrease in the ef the patient was referred for further cardiac evaluation and underwent myocardial perfusion imaging (mpi) which revealed large anteroseptal defect which was only mildly reversible suggestive of anteroseptal infarct or ischemia.Inferior wall had a paradoxical defect which likely due to soft tissue attenuation.Small size, mild intensity inferolateral partially reversible defect was also seen and could be due to ischemia or soft tissue attenuation.Since the mpi results were abnormal, the patient was referred for cardiac catheterization.Four days later, 70% isr was noted in the proximal lad, mild isr in the stent extending into the distal vessel, 70% stenosis in the distal lad.On the same day, the 70% isr in the proximal lad was treated with direct placement of a 3.00x28mm synergy stent.Following post-dilatation, residual stenosis was 0%.On the following day, the event was considered as resolved and the patient was discharged on aspirin and clopidogrel.
 
Manufacturer Narrative
(b)(4).
 
Event Description
It was further reported that the site has confirmed that the study stents placed in the mid lad were patent.The site also confirmed that the study stent placed in the distal lcx was patent.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROMUS ELEMENT¿ PLUS
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC - GALWAY
Manufacturer (Section G)
BOSTON SCIENTIFIC - GALWAY
Manufacturer Contact
sonali arangil
one scimed place
maple grove, MN 55311
7634941700
MDR Report Key6926227
MDR Text Key88931103
Report Number2134265-2017-10004
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P110010
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 09/20/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/07/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date10/14/2013
Device Model NumberH7493911432220
Device Catalogue Number39114-3222
Device Lot Number15698394
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/23/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured11/30/2012
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age61 YR
-
-